Opendata, web and dolomites

Tomo-FPS

Tomosynthesis is a low-dose alternate to has CT already transformed Breast Imaging, our vision is to reduce the costs, further enhance sensitivity and reduce dose, and transform portability.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Tomo-FPS project word cloud

Explore the words cloud of the Tomo-FPS project. It provides you a very rough idea of what is the project "Tomo-FPS" about.

footprint    acquisition    market    ultrasound    workhorse    power    localise    small    diagnostic    magnetic    safer    disease    ray    lung    form    vary    world    90    true    majority    capability    despite    size    tomography    subject    imaging    50    radically    quantify    5bn    limited    accepted    near    resolution    move    cheaper    weight    objectivity    circa    changing    computed    2d    panel    ct    source    versus    bone    mri    dimension    radiation    tomosynthesis    screening    flat    parts    progression    transform    giving    moving    60    demonstrated    medical    planar    offerings    resonance    potentially    emission    nodules    review    global    3d    unlike    healthcare    worldwide    dimensions    innovation    symptomatic    constitutes    speed    adaptix    radiology    image    visualize    reduce    cancer    breast    continues    device    fps    biomarkers    objects    levels    transformed    dose    consistency    reducing    equal    modalities    angle    tissues    basic    performing    closer   

Project "Tomo-FPS" data sheet

The following table provides information about the project.

Coordinator
ADAPTIX LTD 

Organization address
address: BEGBROKE SCIENCE PARK - WOODSTOCK ROAD
city: OXFORD
postcode: OX5 1PF
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.adaptiximaging.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADAPTIX LTD UK (OXFORD) coordinator 50˙000.00

Map

 Project objective

The power of 3D X-ray imaging in healthcare in the form of Computed Tomography (CT) is widely accepted, but despite the widespread availability of CT and Magnetic Resonance Imaging (MRI) it is still the basic 2D planar X-ray that constitutes the majority (circa 60%) of medical imaging studies worldwide. Planar X-ray continues to be the “workhorse of radiology” because of its availability, low cost and small system footprint (compared to MRI and CT); its speed of image acquisition and review (compared to all other modalities); its ability to visualize tissues like bone (unlike MRI and Ultrasound); its low radiation dose (unlike CT); and its consistency and objectivity of image acquisition (unlike Ultrasound).

Tomosynthesis, a method for performing high-resolution limited-angle tomography at low dose levels, has already transformed breast cancer screening and has demonstrated an ability to near-equal CT in identifying lung nodules symptomatic of lung cancer.

Our innovation is a Flat Panel X-ray Source (FPS) that allows tomosynthesis without any moving parts. This will reduce costs and enhance acquisition speed and allows the source to be closer to the subject, reducing power needs and further reducing cost.

Unlike current tomosynthesis devices that move the source in 1 dimension, a system using an FPS could vary emission in 2 dimensions which could enhance depth resolution and the ability to localise objects. This would enhance the ability to quantify features, including biomarkers of disease progression.

Adaptix will transform planar X-ray by giving it true 3D capability, making it safer by reducing dose (versus CT, and potentially versus planar X-ray), making the systems 50% cheaper than existing market offerings and reducing weight and size by 90%. By doing this we will be improving access to the world’s most important medical diagnostic device and radically changing a $5bn global market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOMO-FPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOMO-FPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More